Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Event Reporting
        • Educational Events
        • Non-Price Benefit Reports
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
        • 2019
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • IGBA Global Biosimilars Week
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • IGBA
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2020
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
  • COVID-19 Virus
    • COVID-19 Virus: The Facts
You are here: Home / Latest news / News 2020 / Australian patients must be able to access their medicines without undue delay

Australian patients must be able to access their medicines without undue delay

October 2, 2020 By Admin

30 September 2020

Canberra, ACT

The Generic and Biosimilar Medicines Association looks to create pharmaceutical ‘green lanes’ – through shipping congestion and industrial action – for vital medicines

Canberra: Australia’s peak body for generic and biosimilar medicines has been urgently working with its members and the Australian Government to ensure vital medicines continue to be delivered through the industrial action and ongoing congestion at Australian ports.

CEO of the Generic and Biosimilar Medicines Association (GBMA), Ms Marnie Peterson, said members were concerned about any potential delays to medicines reaching the patients that needed them, in particularly those most vulnerable during the pandemic.

Sydney’s Port Botany is a central pre-wholesale delivery port for the country’s imported pharmaceuticals. From there, medicines are distributed to all parts of Australia.

“GBMA members have been working around the clock for months to do what we can, where we can, to ensure all Australians can continue to access safe and affordable medicines,” Ms Peterson said.

“The safe and timely delivery of our medicines to our patients who are in need is our main priority, and these challenges faced at the Sydney ports comes after months of our members battling high air freight costs, border closures, increasing shipping costs and port congestion.”

With the largest volume percentage of medicines on the PBS being generic products, GBMA is working with the Australian Government and key stakeholders, to understand what, and how many, medicines may be affected and what can be done to identify and mitigate any supply risks.

During the height of the pandemic, GBMA worked with its international colleagues to create pharmaceutical ‘green lanes’ to ensure vital medicines were able to pass through closed borders. It was now hoping to work with all stakeholders, whether a similar system can be established at Australian ports.

Australia has a great health system and a world class supply chain of safe and affordable medicines, but any unintended interference with it can have serious consequences for Australia’s most vulnerable.

GBMA advises Australians who are concerned about the availability of their medicines to check the TGA website link and to discuss their concerns with their healthcare professional.

More information:
Jannette Cotterell
Executive Counsel Australia
0419 204 059
jcotterell@executivecounsel.com.au

–ENDS–

ABOUT GBMA

The Generic and Biosimilar Medicines Association (GBMA) is the peak representative body of generic and biosimilar medicine suppliers in Australia. Its members ensure that all Australians are offered high quality generic and biosimilar medicines, whilst providing affordable community health outcomes that benefit all Australians.

For more information, please contact the GBMA – admin@gbma.com.au or visit www.gbma.com.au

–ENDS–

Filed Under: News 2020

Our Members

Juno
Juno
Sandoz logo
Sandoz logo
Viatris
Viatris
Arrow logo
Arrow logo
apotex
apotex
Celltrion Healthcare
Celltrion Healthcare
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
generic_partners
generic_partners
southern_cross
southern_cross
commercial_eyes
commercial_eyes
sinapse
sinapse

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

Announcement of Independent Chair

December 9, 2020

9 December 2020 Canberra, ACT Global health policy powerhouse, Jane Halton AO PSM, joins GBMA as its inaugural Independent … More...

Confidence in biosimilar medicines, amongst specialists, GP’s and Pharmacists

December 8, 2020

12 November 2020 Canberra, ACT New research shows prescriber … More...

IGBA Launches First Global Biosimilars Week

December 7, 2020

16 November 2020 Geneva, Switzerland Today the International Generic and … More…

© 2021 Generic Medicines Industry Association Pty Ltd | Site Map | Contact Us